SBIR/STTR Research Award

Developing high-affinity nanobodies to tumor-associated glycan antigens

Award identifier fc7df63a148bd5d4ad45ca51d7aa5d11c0f831379df25f43a7e621c519d5ba9cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$149,938

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VITAN-BIOTECH LLC
Proposal award date
2019-08-01
Contract end date
2020-07-31
UEI
ML5NLF9L1FP9
Solicitation number
PA16-157
Topic code
300

Research abstract

Project SummaryGlycans are known to be involved in including cell growth and differentiationcell cell communicationimmune responseand intracellular signaling eventsGlycans also feature prominently in human diseaseIn many different human disordersthe cellular glycome is alteredThe key unsolved problems in the glycosciences are the tools for study the temporal and spatial distribution of glycans on in intact cellswhich is important to the revelation of glycan related biological eventsWe propose to develop a robustintegrated platform for the rapid discovery and characterization of high affinity nanobodiesi esingle domain antibodysdAbsagainst defined glycan structures of biomedical importanceThe proposed project seeks to overcome the critical barriers in producing high affinity glycan specific nanobodiesipoor immunogenicity of glycans iidifficulties and labor intensive nature for immobilization of carbohydrate antigens onto carrier as immunogensIn this Phase I proof of concept demonstrationwe will select and validate high affinity nanobodies to tumor associated glycans antigens of Thomsen Friedenreich antigenTnGal bGalNActhe sialyl TnNeu AcGalNAcantigenand sialyl LewisxNeu AcGalFucGlcNAcThe long term goal is to buildup libraries of nanobodies to a diversity of glycan structuresSuch an effort is anticipated to yield a set of well characterized new glycan specific affinity reagents that are suitable for probing temporal and spatial expression of glycans in cells and tissuesand provide accessible reagents for `non glycoandaposexperts in biology and biomedical field Project NarrativeTo unravel the role that glycans play in both health and diseasenew tools are needed to study the temporal and spatial distribution of glycans on in intact cellsThis proposed research is to develop a robustintegrated platform for the rapid discovery and characterization of high affinity nanobodies against defined glycan structures of biomedical importanceDue to the unique properties of nanobodiessmall sizehigh stabilityand tissue penetrationthe glycan recognizing nanobodies will be suitable for probing the temporal and spatial expression of glycans in cells and tissues

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

9 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $1,791,537. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.